Compare AbCellera Biologics Inc (ABCL) vs ProShares UltraPro Short QQQ ETF (SQQQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs ProShares UltraPro Short QQQ ETF — how do they compare? AbCellera Biologics Inc trades at $7.12 (market cap $2.35B), while ProShares UltraPro Short QQQ ETF trades at $40.85. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, ProShares UltraPro Short QQQ ETF nearer its low. Which is the better fit depends on your goals.
| ABCL | SQQQ | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $8.12 | $97.65 |
52-Week Low | $2.78 | $36.31 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
SQQQ (ProShares UltraPro Short QQQ ETF) declined 4.18% to $38.28, reflecting its bearish inverse leverage strategy against the Nasdaq-100. Technical indicators show a predominantly bearish signal with moving averages indicating strong selling pressure. The ETF's structure as a daily -3x leveraged product creates inherent decay risks, with historical data showing significant long-term value erosion. Recent news highlights concerns about SQQQ's suitability as a long-term investment vehicle.
SQQQ faces structural headwinds from daily reset mechanisms that compound losses in rising markets. While potentially useful for short-term tactical bearish bets, the ETF's design makes it unsuitable for buy-and-hold strategies. Investors seeking Nasdaq-100 exposure should consider the significant risks of value decay and timing sensitivity inherent in leveraged inverse products.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →
